ACHV logo

ACHIEVE LIFE SCIENCES INC

ACHVNASDAQ
πŸ† #2534 by market capEarnings Mar 22 Β· PostUS Equity
$6.78β–² $0.06 (+0.89%)
Market closed Β· at close
πŸ””
Track ACHV
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.9%
7dβ–Ό 0.3%
14dβ–² 0.9%
30dβ–² 4.7%
ytdβ–² 36.1%
1yβ–² 71.9%
🏦Market Cap
$698M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-89.3%
Declining
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
34.0%
Strong
βš–οΈP/S Ratio
39.2x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$6.52 – $6.91
52-Week Range
$2.62 – $8.64
Volume (shares)
1,088,136
Avg Volume (shares)
β€”
Shares Outstanding
102.9M
Next Earnings
2027-03-22

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
$114,000
P/E Ratio
β€”
P/S Ratio
39.2x
EPS (TTM)
$-1.55
Dividend Yield
β€”
Dilution (1yr)
+54.4%
ACHV logo

ACHIEVE LIFE SCIENCES INC

ACHV
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$55Mβ–² +40.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$49Mβ–² +66.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
53.3Mβ–² +54.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6Mβ–² +$3M YoY
StockOtter Β· stockotter.space

About ACHIEVE LIFE SCIENCES INC

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
18 analysts
Strong Buy4
Buy13
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

News unavailable.